EXTEND-I: Safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Acta Ophthalmologica

Volumn 88, Issue 3, 2010, Pages 309-316

  Tano, Yasuo ^a   Ohji, Masahito ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Age related macular degeneration; Best corrected visual acuity score; Choroidal neovascularization; Efficacy; Japanese patients; Ranibizumab; Safety; Subfoveal; Tolerability

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ANGINA PECTORIS; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENOPIA; ATAXIA; BLADDER CANCER; BRAIN HEMORRHAGE; CATARACT; CHEMOSIS; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EDEMA; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE PAIN; EYE TOXICITY; FEMALE; HUMAN; HYPERTENSION; HYPESTHESIA; INTESTINE DIVERTICULOSIS; INTRAOCULAR PRESSURE; IRITIS; JAPANESE; LUNG CARCINOMA; LYMPHANGIECTASIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETINA FOVEA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH CANCER; SUBRETINAL NEOVASCULARIZATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ACUITY; VITREOUS FLOATERS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOVEA CENTRALIS; HUMANS; JAPAN; MACULAR DEGENERATION; MALE; RETREATMENT; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77951734659     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01843.x     Document Type: Article

References (14)

1. Augustin A, Sahel JA, Bandello F, Dardennes R, Maurel F, Negrini C, Hieke K Berdeaux G (2007 Anxiety and depression prevalence rates in age-related macular degeneration. Invest Ophthalmol Vis Sci 48 : 1498 1503.
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP Schneider S (2006 Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 : 1432 1444.
3. Dadgostar H Waheed N (2008 The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye 22 : 761 767.
4. FDA (2006). Highlights of Lucentis prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/125156lbl.pdf.
5. Ferrara N, Damico L, Shams N, Lowman H Kim R (2006 Development of ranibizumab, an antivascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 : 859 870.
6. Hassell JB, Lamoureux EL Keeffe JE (2006 Impact of age related macular degeneration on quality of life. Br J Ophthalmol 90 : 593 596.
7. Hogan M, Kimura S Thygeson P (1959 Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol 47 : 155 170.
8. Japanese Age-Related Macular Degeneration Trial (JAT) Study Group (2003 Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 136 : 1049 1061.
9. Japanese Age-Related Macular Degeneration Trial (JAT) Study Group (2008 Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD): results of the Japanese AMD Trial (JAT) extension. Jpn J Ophthalmol 52 : 99 107.
10. Kawasaki R, Wang JJ, Ji GJ et al. (2008 Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology 115 : 1376 1381.
11. Lowe J, Araujo J, Yang J et al. (2007 Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 85 : 425 430.
12. Nowak JZ (2006 Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 58 : 353 363.
13. Oshima Y, Ishibashi T, Murata T, Tahara Y, Kiyohara Y Kubota T (2001 Prevalence of age related maculopathy in a representative Japanese population: the Hisayama study. Br J Ophthalmol 85 : 1153 1157.
14. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY Kim RY (2006 Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 : 1419 1431.